$CGEM
Cullinan Therapeutics, Inc. Stock $cgem

$cgem Overview Financials Valuation SEC Filings Company Website

2022 Q1 Form 10-K Financial Statement

#000095017022004002 Filed on March 17, 2022

Income Statement

Concept	2022 Q1	2021	2020 Q4
Revenue	$0.00	$18.94M	$0.00
YoY Change	-100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$8.121M	$29.15M	$12.54M
YoY Change	81.27%	70.25%	962.71%
% of Gross Profit
Research & Development	$24.54M	$57.75M	$16.63M
YoY Change	97.63%	33.65%	337.63%
% of Gross Profit
Depreciation & Amortization	$13.00K	$53.00K	$10.00K
YoY Change	-13.33%	-14.52%	-50.0%
% of Gross Profit
Operating Expenses	$32.66M	$86.90M	$29.17M
YoY Change	85.86%	44.02%	485.74%
Operating Profit	-$32.66M	-$67.95M
YoY Change	-2480.25%	12.63%
Interest Expense	$197.0K	$477.0K	$80.00K
YoY Change	294.0%	-46.4%	-68.0%
% of Operating Profit
Other Income/Expense, Net	$0.00	-$8.000K	-$10.00K
YoY Change	-100.0%	-27.27%
Pretax Income	-$32.46M	-$67.49M	-$29.11M
YoY Change	-2387.53%	13.5%	515.43%
Income Tax	-$19.60M	$0.00
% Of Pretax Income
Net Earnings	-$12.10M	-$65.57M	-$28.35M
YoY Change	17182.86%	26.59%	520.35%
Net Earnings / Revenue		-346.14%
Basic Earnings Per Share	-$0.27	-$1.52
Diluted Earnings Per Share	-$272.3K	-$1.522M	-$684.8K
COMMON SHARES
Basic Shares Outstanding	44.61M	43.08M
Diluted Shares Outstanding	44.43M	43.08M

Balance Sheet

Concept	2022 Q1	2021	2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$314.9M	$290.5M	$210.2M
YoY Change	-28.59%	38.19%
Cash & Equivalents	$76.12M	$59.77M	$168.2M
Short-Term Investments	$238.7M	$230.7M	$42.00M
Other Short-Term Assets	$7.458M	$6.098M	$2.100M
YoY Change	16.53%	190.38%
Inventory
Prepaid Expenses	$7.458M		$2.072M
Receivables
Other Receivables
Total Short-Term Assets	$322.3M	$296.6M	$212.3M
YoY Change	-27.94%	39.69%
LONG-TERM ASSETS
Property, Plant & Equipment	$64.00K	$77.00K	$130.0K
YoY Change	-36.0%	-23.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$94.18M	$140.4M
YoY Change	193.39%
Other Assets	$147.0K	$147.0K	$2.300M
YoY Change	47.0%	-93.61%
Total Long-Term Assets	$115.2M	$140.6M	$2.430M
YoY Change	255.4%	5759.21%
TOTAL ASSETS
Total Short-Term Assets	$322.3M	$296.6M	$212.3M
Total Long-Term Assets	$115.2M	$140.6M	$2.430M
Total Assets	$437.5M	$437.2M	$214.7M
YoY Change	-8.8%	103.63%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$6.306M	$3.169M	$9.679M
YoY Change	61.69%	-67.33%
Accrued Expenses	$10.43M	$8.577M	$4.641M
YoY Change	73.87%	86.46%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$17.26M	$11.75M	$14.32M
YoY Change	74.31%	-17.86%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$736.0K	$65.00K	$100.0K
YoY Change	636.0%	-35.0%
Total Long-Term Liabilities	$736.0K	$65.00K	$100.0K
YoY Change	636.0%	-35.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$17.26M	$11.75M	$14.32M
Total Long-Term Liabilities	$736.0K	$65.00K	$100.0K
Total Liabilities	$17.99M	$12.21M	$14.39M
YoY Change	40.57%	-22.2%
SHAREHOLDERS EQUITY
Retained Earnings	-$171.0M		-$93.34M
YoY Change			124.7%
Common Stock	$592.8M		$292.4M
YoY Change			111.02%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$418.7M	$425.0M	$199.0M
YoY Change
Total Liabilities & Shareholders Equity	$437.5M	$437.2M	$214.7M
YoY Change	-8.8%	103.63%

Cashflow Statement

Concept	2022 Q1	2021	2020 Q4
OPERATING ACTIVITIES
Net Income	-$12.10M	-$65.57M	-$28.35M
YoY Change	17182.86%	26.59%	520.35%
Depreciation, Depletion And Amortization	$13.00K	$53.00K	$10.00K
YoY Change	-13.33%	-14.52%	-50.0%
Cash From Operating Activities	-$21.91M	-$43.43M	-$9.430M
YoY Change	1346.07%	45.89%	93.63%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00	$0.00
YoY Change		-100.0%
Acquisitions
YoY Change
Other Investing Activities	$34.71M	-$333.8M	$11.44M
YoY Change	-125.2%	6069.59%	-132.33%
Cash From Investing Activities	$34.71M	-$333.8M	$11.44M
YoY Change	-125.2%	6058.21%	-132.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	3.541M	268.8M	124.9M
YoY Change	-98.66%	91.8%	48.83%
NET CHANGE
Cash From Operating Activities	-21.91M	-43.43M	-9.430M
Cash From Investing Activities	34.71M	-333.8M	11.44M
Cash From Financing Activities	3.541M	268.8M	124.9M
Net Change In Cash	16.34M	-108.4M	126.9M
YoY Change	-86.96%	-203.31%	190.61%
FREE CASH FLOW
Cash From Operating Activities	-$21.91M	-$43.43M	-$9.430M
Capital Expenditures	$0.00	$0.00	$0.00
Free Cash Flow	-$21.91M	-$43.43M	-$9.430M
YoY Change	1346.07%	45.84%	93.63%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2021Q4	us-gaap	Long Term Investments LongTermInvestments	140397000
CY2020Q4	us-gaap	Long Term Investments LongTermInvestments	0
CY2021Q4	us-gaap	Assets Assets	437185000
CY2020Q4	us-gaap	Assets Assets	214708000
CY2021	dei	Entity Registrant Name EntityRegistrantName	CULLINAN ONCOLOGY, INC.
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0001789972
CY2019Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent
CY2021	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://fasb.org/us-gaap/2021-01-31#LicenseMember
CY2019Q4	cgem	Non Voting Incentive Units NonVotingIncentiveUnits
CY2020Q4	cgem	Non Voting Incentive Units NonVotingIncentiveUnits
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2020	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://fasb.org/us-gaap/2021-01-31#LicenseMember
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-12-31
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Entity File Number EntityFileNumber	001-39856
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3169000
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	81-3879991
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	One Main Street
CY2021	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 520
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	Cambridge
CY2021	dei	Entity Address Country EntityAddressCountry	MA
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02142
CY2021	dei	City Area Code CityAreaCode	617
CY2021	dei	Local Phone Number LocalPhoneNumber	410-4650
CY2021	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
CY2021	dei	Trading Symbol TradingSymbol	CGEM
CY2021	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2021	dei	Entity Small Business EntitySmallBusiness	true
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2021	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Public Float EntityPublicFloat	717444028
CY2022Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	44608613
CY2021	dei	Auditor Firm AuditorFirmId	185
CY2021	dei	Auditor Name AuditorName	KPMG LLP
CY2021	dei	Auditor Location AuditorLocation	Boston, Massachusetts
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	59774000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	168198000
CY2021Q4	us-gaap	Short Term Investments ShortTermInvestments	230692000
CY2020Q4	us-gaap	Short Term Investments ShortTermInvestments	42008000
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	6098000
CY2020Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2072000
CY2021Q4	us-gaap	Assets Current AssetsCurrent	296564000
CY2020Q4	us-gaap	Assets Current AssetsCurrent	212278000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	77000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	130000
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	147000
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2300000
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	9679000
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8577000
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4641000
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	11746000
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	14320000
CY2021Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	65000
CY2020Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	74000
CY2021Q4	us-gaap	Liabilities Liabilities	11811000
CY2020Q4	us-gaap	Liabilities Liabilities	14394000
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	34900878
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	44292102
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	44292102
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	29831125
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	29831125
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	4000
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	3000
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	584714000
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	292348000
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-838000
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-158909000
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-93339000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	424971000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	199010000
CY2021Q4	us-gaap	Minority Interest MinorityInterest	403000
CY2020Q4	us-gaap	Minority Interest MinorityInterest	1304000
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	425374000
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	200314000
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	437185000
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	214708000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	18943000
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	57751000
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	43211000
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	29146000
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	17124000
CY2021	us-gaap	Operating Expenses OperatingExpenses	86897000
CY2020	us-gaap	Operating Expenses OperatingExpenses	60335000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-67954000
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-60335000
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	477000
CY2020	us-gaap	Investment Income Interest InvestmentIncomeInterest	888000
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-8000
CY2020Q4	cgem	Number Of Development Subsidiaries NumberOfDevelopmentSubsidiaries	5
CY2021Q1	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	264500000
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-11000
CY2021	us-gaap	Profit Loss ProfitLoss	-67485000
CY2020	us-gaap	Profit Loss ProfitLoss	-59458000
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-1915000
CY2020	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-7659000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-65570000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-51799000
CY2021	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.52
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.60
CY2021	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	43077330
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	19887307
CY2021	us-gaap	Profit Loss ProfitLoss	-67485000
CY2020	us-gaap	Profit Loss ProfitLoss	-59458000
CY2021	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-836000
CY2020	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	2000
CY2021	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-68321000
CY2020	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-59456000
CY2021	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-1915000
CY2020	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-7659000
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-66406000
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-51797000
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	97865000
CY2020	cgem	Common Stock Equivalents Issued Issuance Costs Previously Reported As Series B Preferred Units CommonStockEquivalentsIssuedIssuanceCostsPreviouslyReportedAsSeriesBPreferredUnits	213000
CY2020	cgem	Issuance Of Common Stock Equivalents Previously Reported As Series B Preferred Units IssuanceOfCommonStockEquivalentsPreviouslyReportedAsSeriesBPreferredUnits	14037000
CY2020	cgem	Common Stock Equivalents Issued Issuance Costs Previously Reported As Series C Preferred Units CommonStockEquivalentsIssuedIssuanceCostsPreviouslyReportedAsSeriesCPreferredUnits	6359000
CY2020	cgem	Issuance Of Common Stock Equivalents Previously Reported As Series C Preferred Units IssuanceOfCommonStockEquivalentsPreviouslyReportedAsSeriesCPreferredUnits	124841000
CY2020	us-gaap	Noncontrolling Interest Increase From Business Combination NoncontrollingInterestIncreaseFromBusinessCombination	5673000
CY2020	cgem	Stock Issued During Period Value Subsidiary Preferred Stock StockIssuedDuringPeriodValueSubsidiaryPreferredStock	1206000
CY2020	cgem	Stock Issued During Period Value Subsidiary Common Stock StockIssuedDuringPeriodValueSubsidiaryCommonStock	1183000
CY2020	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	14910000
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	56000
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	2000
CY2020	us-gaap	Profit Loss ProfitLoss	-59458000
CY2020Q4	cgem	Stockholders Equity Including Portion Attributable To Noncontrolling Interests StockholdersEquityIncludingPortionAttributableToNoncontrollingInterests	200315000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	22870000
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	264516000
CY2021	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	218000
CY2021	cgem	Stock Issued During Period Value Subsidiary Preferred Stock StockIssuedDuringPeriodValueSubsidiaryPreferredStock	923000
CY2021	cgem	Stock Issued During Period Value Subsidiary Common Stock StockIssuedDuringPeriodValueSubsidiaryCommonStock	67000
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	24375000
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3281000
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-836000
CY2021	us-gaap	Profit Loss ProfitLoss	-67485000
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	425374000
CY2021	us-gaap	Profit Loss ProfitLoss	-67485000
CY2020	us-gaap	Profit Loss ProfitLoss	-59458000
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	53000
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	62000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	24375000
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	14910000
CY2021	cgem	Amortization Accretion On Marketable Securities AmortizationAccretionOnMarketableSecurities	3098000
CY2020	cgem	Amortization Accretion On Marketable Securities AmortizationAccretionOnMarketableSecurities	233000
CY2021	cgem	License Expense In Exchange For Subsidiary Common Stock LicenseExpenseInExchangeForSubsidiaryCommonStock	67000
CY2020	cgem	License Expense In Exchange For Subsidiary Common Stock LicenseExpenseInExchangeForSubsidiaryCommonStock	1183000
CY2020	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	6447000
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3269000
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	462000
CY2020	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	18000
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-4835000
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	5581000
CY2021	cgem	Increase Decrease In Accrued Expenses And Other Current Liabilities IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities	4563000
CY2020	cgem	Increase Decrease In Accrued Expenses And Other Current Liabilities IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities	1750000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-43433000
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-29772000
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	10000
CY2020	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	-1450000
CY2021	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	525813000
CY2020	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	69763000
CY2021	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	192038000
CY2020	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	62903000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-333775000
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5420000
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	145450000
CY2021	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	267268000
CY2020	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	6572000
CY2021	cgem	Payment Of Deferred Offering Costs PaymentOfDeferredOfferingCosts	2688000
CY2021	us-gaap	Proceeds From Payments To Minority Shareholders ProceedsFromPaymentsToMinorityShareholders	923000
CY2020	us-gaap	Proceeds From Payments To Minority Shareholders ProceedsFromPaymentsToMinorityShareholders	1206000
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	3281000
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	56000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	268784000
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	140140000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-108424000
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	104948000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	168198000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	63250000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	59774000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	168198000
CY2021	cgem	Deferred Offering Costs Paid In Prior Year DeferredOfferingCostsPaidInPriorYear	65000
CY2020	cgem	Deferred Offering Costs In Accounts Payable And Accrued Expenses DeferredOfferingCostsInAccountsPayableAndAccruedExpenses	2093000
CY2021Q4	cgem	Number Of Development Subsidiaries NumberOfDevelopmentSubsidiaries	4
CY2021Q4	cgem	Cash Cash Equivalents Short Term Investments CashCashEquivalentsShortTermInvestments	290500000
CY2021	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	one-for-7.0390
CY2021	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	1
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-158900000
CY2021Q4	us-gaap	Long Term Investments LongTermInvestments	140400000
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Use of Estimates</span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of the accompanying consolidated financial statements in accordance with GAAP requires the Company’s management to make estimates and judgments that may affect the reported amounts of assets, liabilities, revenues, expenses and related disclosure of contingent assets and liabilities. On an ongoing basis, the Company’s management evaluates the estimates, including those related to expenses and accruals. The Company’s management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the fair value of the royalty transfer agreements, accrued research and development costs, the valuation of acquired in-process research and development asset and the fair value of equity awards issued by the Company and its subsidiaries prior to the IPO. Actual results may differ from these estimates under different assumptions or conditions.</span>
CY2021	us-gaap	Income Loss Attributable To Noncontrolling Interest IncomeLossAttributableToNoncontrollingInterest	1900000
CY2020	us-gaap	Income Loss Attributable To Noncontrolling Interest IncomeLossAttributableToNoncontrollingInterest	7700000
CY2021	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-800000
CY2021	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1
CY2021	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2021	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Concentration of Credit Risk and Other Risks and Uncertainties</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has no significant off-balance sheet risk. Cash and cash equivalents are primarily maintained with two major financial institutions in the United States. Deposits at banks may exceed the insurance provided on such deposits. These deposits may be redeemed upon demand, and therefore, bear minimal risk.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company is subject to certain risks and uncertainties and believes that changes in any of the following areas could have a material adverse effect on future financial position or results of operations: ability to obtain future financing; regulatory approval and market acceptance of, and reimbursement for, product candidates; performance of third-party clinical research organizations and manufacturers upon which the Company relies; protection of the Company’s intellectual property; litigation or claims against the Company based on intellectual property, patent, product, regulatory or other factors; and the Company’s ability to attract and retain employees necessary to support its growth.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company is dependent on third-party manufacturers to supply products for research and development activities in its programs. In particular, the Company relies and expects to continue to rely on a small number of manufacturers to supply it with its requirements for drug substance and drug products related to these programs. These programs could be adversely affected by a significant interruption in the supply.</span>
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	371927000
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	838000
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	371089000
CY2020Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	2700000
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	309000
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	309000
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	232000
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	179000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	77000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	130000
CY2021Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	2576000
CY2020Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	1763000
CY2021Q4	cgem	Accrued Professional Fees And Other Current AccruedProfessionalFeesAndOtherCurrent	973000
CY2020Q4	cgem	Accrued Professional Fees And Other Current AccruedProfessionalFeesAndOtherCurrent	1049000
CY2021Q4	cgem	Accrued Research And Development Costs AccruedResearchAndDevelopmentCosts	5028000
CY2020Q4	cgem	Accrued Research And Development Costs AccruedResearchAndDevelopmentCosts	1829000
CY2021Q4	cgem	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	8577000
CY2020Q4	cgem	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	4641000
CY2021	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2020	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2021	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	1
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	3000
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	292348000
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2000
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-93339000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	199010000
CY2020Q4	us-gaap	Minority Interest MinorityInterest	1304000
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	200314000
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	2000
CY2019Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	138543000
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4000
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-41540000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	97001000
CY2019Q4	us-gaap	Minority Interest MinorityInterest	864000
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	97865000
CY2021	us-gaap	Common Stock Voting Rights CommonStockVotingRights	Each share of common stock entitles the holder to one vote and to receive dividends when and if declared by the board of directors of the Company.
CY2021Q4	us-gaap	Dividends Payable Current And Noncurrent DividendsPayableCurrentAndNoncurrent	0
CY2021	cgem	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	0.0001
CY2020	cgem	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	-0.0001
CY2021	cgem	Voting Agreement Description VotingAgreementDescription	Voting Agreement dated May 28, 2020, among the Company and other stockholders of MICA, MICA increased the size of its board of directors from four to five directors, of which three directors are designated by the Company.
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	34900878
CY2019Q4	cgem	Non Voting Incentive Outstanding Unvested Number Of Units NonVotingIncentiveOutstandingUnvestedNumberOfUnits	580334
CY2019Q4	cgem	Non Voting Incentive Units Outstanding Unvested Weighted Average Grant Date Fair Value Per Unit NonVotingIncentiveUnitsOutstandingUnvestedWeightedAverageGrantDateFairValuePerUnit	0.0001
CY2020	cgem	Non Voting Incentive Vested Number Of Units NonVotingIncentiveVestedNumberOfUnits	407844
CY2020	cgem	Non Voting Incentive Units Vested Weighted Average Grant Date Fair Value Per Unit NonVotingIncentiveUnitsVestedWeightedAverageGrantDateFairValuePerUnit	0.0001
CY2020Q4	cgem	Non Voting Incentive Outstanding Unvested Number Of Units NonVotingIncentiveOutstandingUnvestedNumberOfUnits	172490
CY2020Q4	cgem	Non Voting Incentive Units Outstanding Unvested Weighted Average Grant Date Fair Value Per Unit NonVotingIncentiveUnitsOutstandingUnvestedWeightedAverageGrantDateFairValuePerUnit	0.0001
CY2021	cgem	Non Voting Incentive Vested Number Of Units NonVotingIncentiveVestedNumberOfUnits	172490
CY2021	cgem	Non Voting Incentive Units Vested Weighted Average Grant Date Fair Value Per Unit NonVotingIncentiveUnitsVestedWeightedAverageGrantDateFairValuePerUnit	0.0001
CY2021Q4	cgem	Non Voting Incentive Outstanding Unvested Number Of Units NonVotingIncentiveOutstandingUnvestedNumberOfUnits	0
CY2021Q4	cgem	Non Voting Incentive Units Outstanding Unvested Weighted Average Grant Date Fair Value Per Unit NonVotingIncentiveUnitsOutstandingUnvestedWeightedAverageGrantDateFairValuePerUnit	0.0001
CY2021Q4	cgem	Non Voting Incentive Outstanding Vested Number Of Units NonVotingIncentiveOutstandingVestedNumberOfUnits	1689949
CY2020Q4	cgem	Non Voting Incentive Units Outstanding Vested Weighted Average Grant Date Fair Value Per Unit NonVotingIncentiveUnitsOutstandingVestedWeightedAverageGrantDateFairValuePerUnit	0.0001
CY2020Q4	cgem	Stock Purchased During Period Shares StockPurchasedDuringPeriodShares	2254231
CY2020Q4	cgem	Common Stock Exchange In Excess Fair Value CommonStockExchangeInExcessFairValue	1200000
CY2021Q1	us-gaap	Stock Issued During Period Shares Conversion Of Units StockIssuedDuringPeriodSharesConversionOfUnits	320228
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	44552000
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	22642000
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	24375000
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	14910000
CY2021	cgem	Management And Advisory Services ManagementAndAdvisoryServices	0
CY2020	cgem	Management And Advisory Services ManagementAndAdvisoryServices	200000
CY2021	cgem	Royalty Percentage RoyaltyPercentage	0.010
CY2021	us-gaap	Royalty Expense RoyaltyExpense	0
CY2020	us-gaap	Royalty Expense RoyaltyExpense	0
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0996
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.0183
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	8000
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	44544000
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	0.0039
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.0190
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0000
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0000
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	31414000
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	18563000
CY2020Q4	cgem	Deferred Tax Assets Licenses DeferredTaxAssetsLicenses	1601000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	968000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	467000
CY2021Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	1563000
CY2020Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	1859000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	8584000
CY2021	us-gaap	Unrecognized Tax Benefits Period Increase Decrease UnrecognizedTaxBenefitsPeriodIncreaseDecrease	0
CY2021Q4	cgem	Deferred Tax Assets Capitalized Organizational And Startup Expenses DeferredTaxAssetsCapitalizedOrganizationalAndStartupExpenses	140000
CY2020Q4	cgem	Deferred Tax Assets Capitalized Organizational And Startup Expenses DeferredTaxAssetsCapitalizedOrganizationalAndStartupExpenses	148000
CY2021Q4	cgem	Deferred Tax Assets Licenses DeferredTaxAssetsLicenses	1875000
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	11989000
CY2021	cgem	Valuation Allowance Deferred Tax Asset Increases Recorded To Oci Or Equity ValuationAllowanceDeferredTaxAssetIncreasesRecordedToOciOrEquity	236000
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.0025
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.0077
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.3212
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.1265
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Exempt Income EffectiveIncomeTaxRateReconciliationTaxExemptIncome	-0.0501
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	-0.0228
CY2021	cgem	Effective Income Tax Rate Reconciliation Change In Tax Status EffectiveIncomeTaxRateReconciliationChangeInTaxStatus	0.0176
CY2021	cgem	Effective Income Tax Rate Reconciliation Return To Provision EffectiveIncomeTaxRateReconciliationReturnToProvision	0.0115
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	22646000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	44552000
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	22642000
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	8000
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	4000
CY2021Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	8000
CY2020Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	4000
CY2021	us-gaap	Operating Loss Carryforwards Limitations On Use OperatingLossCarryforwardsLimitationsOnUse	an ownership change as defined by Section 382 results from transactions increasing the ownership of certain shareholders or public groups in the stock of a corporation by more than 50 percentage points over a three-year period.
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	22642000
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	10653000
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	21674000
CY2020	us-gaap	Unrecognized Tax Benefits Period Increase Decrease UnrecognizedTaxBenefitsPeriodIncreaseDecrease	0
CY2021Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2020Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2021	us-gaap	Operating Lease Expense OperatingLeaseExpense	600000
CY2020	us-gaap	Operating Lease Expense OperatingLeaseExpense	600000
CY2017Q4	cgem	Operating Lease Commence Date OperatingLeaseCommenceDate	2018-02-01
CY2021	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2024-06-30
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	608000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	618000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	313000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1539000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-65570000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-51799000
CY2021	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	43077330
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	19887307
CY2021	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.52
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.60
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9347622
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4967497

Files In Submission

Name	View Source	Status
0000950170-22-004002-index-headers.html	Edgar Link	pending
0000950170-22-004002-index.html	Edgar Link	pending
0000950170-22-004002.txt	Edgar Link	pending
0000950170-22-004002-xbrl.zip	Edgar Link	pending
cgem-20211231.htm	Edgar Link	pending
cgem-20211231.xsd	Edgar Link	pending
cgem-20211231_cal.xml	Edgar Link	unprocessable
cgem-20211231_def.xml	Edgar Link	unprocessable
cgem-20211231_htm.xml	Edgar Link	completed
cgem-20211231_lab.xml	Edgar Link	unprocessable
cgem-20211231_pre.xml	Edgar Link	unprocessable
cgem-ex10_23.htm	Edgar Link	pending
cgem-ex21_1.htm	Edgar Link	pending
cgem-ex23_1.htm	Edgar Link	pending
cgem-ex31_1.htm	Edgar Link	pending
cgem-ex31_2.htm	Edgar Link	pending
cgem-ex32_1.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
img65927005_0.jpg	Edgar Link	pending
img65927005_1.jpg	Edgar Link	pending
img65927005_10.jpg	Edgar Link	pending
img65927005_11.jpg	Edgar Link	pending
img65927005_12.jpg	Edgar Link	pending
img65927005_13.jpg	Edgar Link	pending
img65927005_14.jpg	Edgar Link	pending
img65927005_15.jpg	Edgar Link	pending
img65927005_16.jpg	Edgar Link	pending
img65927005_17.jpg	Edgar Link	pending
img65927005_18.jpg	Edgar Link	pending
img65927005_19.jpg	Edgar Link	pending
img65927005_2.jpg	Edgar Link	pending
img65927005_20.jpg	Edgar Link	pending
img65927005_21.jpg	Edgar Link	pending
img65927005_22.jpg	Edgar Link	pending
img65927005_23.jpg	Edgar Link	pending
img65927005_24.jpg	Edgar Link	pending
img65927005_25.jpg	Edgar Link	pending
img65927005_26.jpg	Edgar Link	pending
img65927005_27.jpg	Edgar Link	pending
img65927005_28.jpg	Edgar Link	pending
img65927005_29.jpg	Edgar Link	pending
img65927005_3.jpg	Edgar Link	pending
img65927005_30.jpg	Edgar Link	pending
img65927005_31.jpg	Edgar Link	pending
img65927005_32.jpg	Edgar Link	pending
img65927005_33.jpg	Edgar Link	pending
img65927005_34.jpg	Edgar Link	pending
img65927005_35.jpg	Edgar Link	pending
img65927005_36.jpg	Edgar Link	pending
img65927005_37.jpg	Edgar Link	pending
img65927005_38.jpg	Edgar Link	pending
img65927005_39.jpg	Edgar Link	pending
img65927005_4.jpg	Edgar Link	pending
img65927005_40.jpg	Edgar Link	pending
img65927005_41.jpg	Edgar Link	pending
img65927005_42.jpg	Edgar Link	pending
img65927005_43.jpg	Edgar Link	pending
img65927005_44.jpg	Edgar Link	pending
img65927005_5.jpg	Edgar Link	pending
img65927005_6.jpg	Edgar Link	pending
img65927005_7.jpg	Edgar Link	pending
img65927005_8.jpg	Edgar Link	pending
img65927005_9.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CGEM
Cullinan Therapeutics, Inc. Stock $cgem

2022 Q1 Form 10-K Financial Statement

#000095017022004002 Filed on March 17, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CGEM Cullinan Therapeutics, Inc. Stock $cgem

2022 Q1 Form 10-K Financial Statement

#000095017022004002 Filed on March 17, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CGEM
Cullinan Therapeutics, Inc. Stock $cgem